Next Article in Journal
In Vitro Microevolution and Co-Selection Assessment of Florfenicol Impact on Escherichia coli Resistance Development
Previous Article in Journal
Susceptibility Profile and Epidemiological Cut-Off Values Are Influenced by Serotype in Fish Pathogenic Streptococcus agalactiae
Previous Article in Special Issue
Identification of IncA Plasmid, Harboring blaVIM-1 Gene, in S. enterica Goldcoast ST358 and C. freundii ST62 Isolated in a Hospitalized Patient
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 12
10.3390/antibiotics12121727
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Interhospital Spread of blaVIM-1- and blaCTX-M-15-Producing K. pneumoniae ST15 on an IncR Plasmid in Southern Spain

by
Patricia Pérez-Palacios
1,2,
Ana Gual-de-Torrella
1,
Ines Portillo-Calderón
1,2,
Esther Recacha-Villamor
1,2,3,
Francisco Franco-Álvarez de Luna
4,
Lorena Lopez-Cerero
1,2,3,5,* and
Alvaro Pascual
1,2,3,5
1
Division of Infectious Diseases and Microbiology, University Hospital Virgen Macarena, 41009 Seville, Spain
2
Institute of Biomedicine of Sevilla, 41013 Seville, Spain
3
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain
4
Servicio de Microbiología, Hospital Universitario Juan Ramón Jiménez, 21005 Huelva, Spain
5
Departamento de Microbiología, Facultad de Medicina, Universidad de Sevilla, 41009 Seville, Spain
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(12), 1727; https://doi.org/10.3390/antibiotics12121727
Submission received: 15 November 2023 / Revised: 1 December 2023 / Accepted: 7 December 2023 / Published: 13 December 2023
(This article belongs to the Special Issue Antibiotics Resistance and Molecular Epidemiology of Carbapenem-Resistance Bacteria)
Browse Figures
Review Reports Versions Notes

Abstract

:
In 2014–2015, the main CTX-M-15- and OXA-48-producing clone in our region was ST15. Recently, K. pneumoniae ST15 isolates co-producing VIM-1 and CTX-M-15 were detected in several hospitals. The aim was to study the emergence and acquisition of this carbapenemase. Between 2017 and 2019, four hospitals submitted twenty-nine VIM-1- and CTX-M-15-producing K. pneumoniae ST15 isolates to our laboratory. Seven representatives of each XbaI PFGE pulsotype were sequenced using short- and long-read technologies. RAST, CGE databases, and Pathogenwatch were used for resistance determinants and capsule-type analysis. Plasmid comparison was performed with Easyfig2.1. Phylogenetic analysis included other contemporary ST15 isolates from Spain. The 29 isolates were clustered into seven different pulsotypes. The selected genomes, from three hospitals in two different provinces, were clustered together (fewer than 35 alleles) and differed by more than 100 alleles from other ST15 isolates obtained in the region. These seven isolates harbored one IncR plasmid (200–220 kb) with a common backbone and four regions flanked by IS26: one contained blaVIM-1, another contained blaCTX-M-15, the third contained blaOXA-1, and the fourth harbored heavy-metal-tolerance genes. The two initial plasmids, from two different centers, were identical, and rearrangement of four regions was observed in the five subsequent plasmids. Our findings showed the first intercenter dissemination of IncR plasmids carrying blaVIM-1, blaCTX-M-15, and metal-tolerance genes mediated by a new lineage of K. pneumoniae ST15. Two different capture events of the blaVIM-1 gene or different IS26-mediated plasmid rearrangements from a common ancestor may explain plasmid variations.

1. Introduction

Carbapenemase production is a serious health concern in infectious diseases and is becoming a real threat to global health [1]. An important part of this problem involves the increase in carbapenem resistance in Enterobacterales, which was declared a top priority for action by the WHO in 2017 [2]. Rapid identification and monitoring of carbapenem-resistant Gram-negative bacteria is necessary to tackle and control their spread [3]. Among Enterobacterales, Klebsiella pneumoniae is characterized by its extraordinary ability to spread in the community, spread in hospitals [4], and acquire carbapenemase genes. Dissemination has been associated in the last decade with broadly resistant clones with a high capacity for survival and niche colonization, as well as a considerable ability to capture virulence and resistance genes through mobile elements, such as plasmids and transposons, and to transfer them to their progeny or to other species [5].
The ST15 clone is one of the high-risk clones of K. pneumoniae that has worldwide distribution and, together with clones ST11, ST258/512, ST307, and ST147, is responsible for the spread of extended-spectrum beta-lactamases (ESBLs) and carbapenemases [6]. Associations between plasmids and prevalent bacterial clones are extremely frequent [7]. These particular associations have been extensively studied for K. pneumoniae ST11 and ST405 in association with the pOXA-48 plasmid [8], but similar studies for clone ST15 are scarce. In Andalusia, the ST15 and ST11 clones of K. pneumoniae have been one of the main lineages spreading blaOXA-48 and blaCTX-M-15 since 2014 [9]. Recently, isolates of this clone producing blaVIM-1, together with blaCTX-M-15, have been detected in several hospitals in our region. The aim of this study was to characterize these isolates, determine the phylogenetic relationships between them, and analyze the plasmid profile in order to determine whether the increase was due to several independent events or to the geographic spread of a single lineage.

2. Results

The 29 K. pneumoniae ST15 strains co-producing VIM-1 and CTX-M-15 were collected from different sources. Nineteen (65.5%) isolates were recovered from clinical samples: seven (24.1%) from urine samples, four (13.8%) from blood cultures, five (17.2%) from skin and soft-tissue samples, and three (10.3%) from respiratory samples. Ten (34.5%) isolates were collected from surveillance samples (rectal swabs) (Table 1).
By PFGE, seven pulsotypes were detected: P1 (n = 4), P2 (n = 3), P3 (n = 3), P4 (n = 7), P5 (n = 4), P6 (n = 1), and P7 (n = 7) (Supplementary Figure S1). The first isolate, from a blood culture, was detected in August 2017 at the Hospital Infanta Elena in Huelva. One month later, a second isolate was detected in the same hospital in a urine sample. Both isolates were identical by PFGE. Six months later, in March 2018, a third isolate was detected in a rectal swab sample from a patient, transferred from Hospital Infanta Elena, at the Hospital Virgen Macarena in Seville (Figure 1). This third isolate was assigned to a different pulsotype. During 2018, seven more isolates were detected: six between May and November at the Hospital Infanta Elena, where all patients were admitted to the same medical unit, and the last one in December at the Hospital Virgen Macarena (the reference center for the other hospitals). In 2019, the number of isolates increased to 19, and these isolates were detected in four hospitals in our region: 3 isolates at Hospital Juan Ramón Jiménez (Huelva), 14 at the Hospital Macarena (Seville), 1 at the Hospital Infanta Elena (Huelva), and 1 at the Hospital de la Merced (Seville). The patients admitted to the Hospital Virgen Macarena had also been admitted to the same medical unit (Figure 1). As in the previous year, the origin of the isolates was diverse, and all were distributed among the seven different pulsotypes. The annual increase is shown in Table 1. All isolates were assigned to the KL64 O2v1 capsule type (Table 1). The following control measures were implemented in the four centers: terminal cleaning after patient discharge, isolation of positive patients, and electronic tagging of colonized patients for isolation in case of new admissions.
Despite the differences observed by PFGE, when the Ridom cgMLST scheme was used, the seven selected representative pulsotypes belonged to the same core-genome sequence (cgST3266) and were detected in three centers (Table 1). A close genetic relationship was found between the seven genomes: fewer than 10 alleles among six genomes recovered from two centers in the same province (Huelva) and the reference hospital (Hospital Virgen Macarena, Seville) and one isolate differed by 27–33 alleles (Supplementary Figure S2). The latter isolate was recovered from a patient admitted to the reference hospital, and an epidemiological link was established with the Hospital Infanta Elena. All seven genomes were different (more than 100 alleles of difference) from other ST15 isolates from other centers in the region, as well from the two other VIM-1 producers detected in Spain in other regions in 2013–2014, indicating a new lineage.
All isolates were resistant to piperacillin/tazobactam, cefotaxime, cefepime, ertapenem, meropenem, imipenem, gentamicin, tobramycin, ciprofloxacin, and sulfamethoxazole-trimethoprim and susceptible to amikacin, fosfomycin, and colistin. In addition to the blaCTX-M-15 and blaVIM-1 genes, the isolates also harbored other determinants of resistance: to aminoglycosides (aac(3)-IIa, aac(6′)-Ib-cr, aph(6)-Id, aph(3″)-Ib, and aph(3′)-Ia), quinolones (qnrB1 and qnrB2), and folate antagonists (sul1, sul2, and dfrA12) (Supplementary Table S1).
Plasmid analysis of the seven genomes revealed that the blaVIM-1 and blaCTX-M-15 genes were on the same type of plasmid belonging to the IncR incompatibility group and approximately 200,000 pb in size (Figure 2). Comparative genomic analysis showed that the seven plasmids shared the same backbone and three identical regions flanked by IS26s. The two plasmids from 2017 and 2018 were identical but came from two different centers in Huelva. In the rest of the five plasmids, the order of the four regions within the plasmids was different and showed rearrangements (Figure 2). The blaVIM-1 region (approx. 20,000 bp) was located in a class 1 integron, flanked on each side by IS26. Next to blaVIM-1, other antimicrobial-resistance genes, to aminoglycosides (aac(6′)-Ib-cr and aadA1), sulfonamides (sul1), and quinolones (qnrB2), were detected (Figure 2). The regions containing blaCTX-M-15 (approx. 28,000 bp) and blaOXA-1 (approx. 12,000 bp) were also flanked on each side by IS26. The blaCTX-M-15 region included blaTEM-1B, and other aminoglycoside-resistance genes (aph(3′)-Ib, aph(6′)-Id, and aac(3′)-Ib-cr) and the blaOXA-1 region included the aac(6′)-Ib-cr gene. In addition, a third region of approx. 40,000 bp, also flanked by IS26, carried the copper-resistance operon (copABCDRSE), silver-tolerance (silESRCFBAP) genes, and the arsenic-resistance operon (arsRDABCH) (Figure 2).

3. Discussion

In this study, the characteristics of K. pneumoniae ST15 co-producing blaVIM-1 and blaCTX-M-15 on an IncR plasmid indicate that this is a new lineage within clone ST15 that has been spreading among different hospitals in our region since 2017. This clone was found prevalent in our region during 2014–2015 but was mainly associated with the resistant determinants blaCTX-M-15 and blaOXA-48 [9].
With respect to the specific association between clones and plasmids, about which we have less knowledge in ST15, IncR has been linked to the dissemination of the clone ST15 and CTX-M-15 in Portugal (six isolates) and in four geographical areas of Bulgaria [10,11]. In this study, all isolates carried an IncR plasmid, which, in addition to harboring the blaVIM-1- and blaCTX-M-15-resistance determinants, also carried others encoding resistance to aminoglycosides, sulfonamides, and quinolones. The same plasmid was also found to be prevalent among ST15 isolates in our area in 2014–2015 [9]. These findings suggest that the current VIM-1- and CTX-M-15-producing isolates may have emerged from a population already endemic in our area that carried CTX-M-15. On the other hand, several genes for resistance to copper, silver, and arsenic were also detected in this plasmid. The presence of metal and antibiotic-resistance genes in the same mobile elements could imply contaminated environmental reservoirs exerting positive selection pressure on tolerant bacteria, favoring the co-transfer of carbapenemase and metal genes [12].
In our region, since 2014 and 2015, K. pneumonia ST15 has mainly co-produced blaOXA-48, located on IncM and IncL plasmids, and blaCTX-M-15, located on IncR plasmids [9]. The presence of blaVIM-1 in a region flanked by IS26 could indicate that the IncR plasmid containing blaCTX-M-15 captured this carbapenemase, which resulted, over time, in different rearrangements within the plasmid. IS26 is a mobile element of great importance in the dissemination of antibiotic-resistance determinants in Enterobacterales, driving rearrangements and remodeling within the plasmid [13]. Replication of the IS26 transposase, Tnp26, results in the movement of sites flanked by this element, leading to mobilization to new sites and deletion or inversion of adjacent DNA [14]. The dynamic evolution of plasmids and regions mediated by IS26 has already been described; it has also been suggested that blaSHV, originally on the K. pneumoniae chromosome, was mobilized to a plasmid by an IS26-mediated event [15,16]. Further studies are needed to understand the implications of these genetic events for the evolution and diversity of plasmids containing carbapenem-resistance genes when IS26 is present [17].
Studies describing outbreaks caused by K. pneumoniae ST15 have mainly been associated with blaKPC-2- and blaVIM-1-type carbapenemases and have focused on studying its capacity for dissemination in intensive-care-unit patients and on the great difficulty of controlling its spread [18,19,20]. There has also been one study reporting inter-regional spread of K. pneumoniae ST15, although in that case, it was only associated with ESBL and was the result of transferring patients between different hospitals [21]. To date, intercenter dissemination of blaVIM-1- and blaCTX-M-15-producing isolates has not been described. VIM-1-producing K. pneumoniae ST15 has been detected previously in our country, in a European study conducted in 2013–2014, but those isolates were different from the ones found in this study. In our case, the close genetic relatedness of six of the seven isolates could indicate transmission due to regional spread, although data from an epidemiological survey of all cases are not available. Transmission could have occurred during routine transfers between centers: all the isolates were recovered either from two centers in the same city or from the reference hospital. Although the close relationship is suggestive of intrahospital transmission, genetic proximity could also be due to admissions of already colonized patients from other hospitals with which there is a high frequency of patient exchanges, as was observed in the genetically nearest-neighbor analysis carried out by David et al. [22].
Controlling the spread of multidrug-resistant bacteria is currently one of the challenges facing global epidemiology. Therefore, measures and interventions aimed at preventing interregional transmission are very important [23]. One measure that has been shown to have an impact on the control of multidrug-resistant microorganisms is the screening of patients on admission, especially in critical services such as intensive care [24]. Since 2018, colonized patients are routinely electronically flagged in our local region: any colonized patient is preventively isolated on every new admission to any center in the region, and the alert is maintained for 12 months. Measures of this type could have been the first line of defense to prevent the spread of certain successful clones, although full implementation was delayed in the early years, hindering rapid detection among new admissions and enabling the intercenter spread observed in 2019.
A major limitation of this study is that isolates are submitted to the reference laboratory on a voluntary basis and, although the Regional Ministry of Health recommends that all carbapenemase-producing isolates be tested, it is not mandatory. Another important limitation of our study is the lack of epidemiological data on the cases, so there is a possibility of discrepancies between the results obtained in the genetic studies and the epidemiological data. Therefore, in order to have an overall view of the problem of intercenter dissemination, every effort should be made to collect both genetic and epidemiological data. Moreover, the carrier status of the patients was not known prior to admission, so it was difficult to determine the time of acquisition and direction of spread between centers.

4. Materials and Methods

4.1. Bacterial Strains: Collection and Identification

Between 2017 and 2019, four hospitals submitted a total of 29 isolates of VIM-1- and CTX-M-1-producing K. pneumoniae ST15 to the Regional Reference Laboratory for the Surveillance and Control of Nosocomial Infections and Prudent Use of Antimicrobials (PIRASOA) program (Hospital Universitario Virgen Macarena, Seville) for the region of Andalusia, Spain. The isolates originated from 4 hospitals located in 2 adjacent provinces (Seville and Huelva) in Western Andalusia: Hospital Virgen Macarena (n = 16) and Hospital de la Merced (n = 1) in Seville and Hospital Juan Ramón Jiménez (n = 3) and Hospital Infanta Elena (n = 9) in Huelva (Table 1). Hospital Virgen Macarena is the reference hospital for several surgeries (cardiac, thoracic, dermatologic, maxillofacial, plastic, and ophthalmic) for the other three hospitals. All isolates were identified by using MALDI-TOF MS (MALDI-TOF Biotyper 3.1; Microflex Bruker, Madrid, Spain).

4.2. Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing of all isolates was performed using the commercial MicroScan NMDRM1 panel (Beckman Coulter, West Sacramento, CA, USA). Assignment to a clinical category was based on EUCASTv21 breakpoints. Preliminary detection of carbapenemase production was carried out by enzymatic assay (β-carba, Biorad, Marnes-la-Coquette—France) and lateral immunochromatography (NG-Test CARBA-5, NG Biotech, Guipry, France).

4.3. Molecular Typing

Clonal relatedness was initially performed by pulsed-field-gel-electrophoresis (PFGE) analysis of XbaI-digested DNA (http://www.cdc.gov/pulsenet accesed on 10 November 2023). Isolates differing by one or more bands by PFGE were assigned to different pulsotypes [25]. A dendrogram was created using BioNumerics v.7.6 software (Applied Maths, Marcy-l’Étoile, France) using the Dice coefficient with 0.8% optimization and 1% band-position tolerance (Supplementary Figure S1). A representative isolate from each pulsotype was selected for short- and long-read whole-genome sequencing; 3 of the 4 centres were covered.
Ridom SeqSphere+ (v8.1.0) was used for core-genome (cgMLST) and whole-genome (wgMLST) genotyping, as well as minimum-spanning-tree construction, comparing 2358 loci and considering sequence types that differed by more than 15 alleles as different. For comparison purposes, 13 contemporary genomes belonging to ST15 from the Andalusian Reference Regional Laboratory and other centers in the region were added (9 CTX-M-15-producers, 2 hyperproducers of SHV-1, and 2 OXA-48 and CTX-M-15 co-producers), as well as 2 genomes of VIM-1-producing ST15 isolates from other Spanish regions included in a European survey conducted in 2013 and 2014 [26]. A cut-off threshold of 10 alleles in the wgMLST Ridom scheme was used to define an interhospital transmission event [27,28]. A matrix of allele differences was constructed using the whole genome and the first VIM-1- and CTX-M-15-producing K. pneumoniae ST15 isolate as a reference (Supplementary Figure S2).

4.4. Whole-Genome Sequencing (WGS)

DNA extraction was performed with the MagCore HF16 Plus automatic system (RCB Bioscience®, Nottingham, UK). For short-read sequencing, library preparation was performed using the Nextera Flex DNA library preparation kit (Illumina®, San Diego, CA, USA). DNA sequencing was performed with the MiSeq Reagent Kit V3 (Illumina®, San Diego, CA, USA) (600 cycles) and the Illumina MiSeq sequencer (2 × 300 paired-end reads). Raw reads were trimmed, quality filtered, and then assembled de novo with CLC Genomic Workbench v9 (Qiagen, Beverly, MA, USA).
Annotation of antimicrobial-resistance determinants was carried out using ResFinder 4.1 (https://cge.cbs.dtu.dk/services/ResFinder/ (accessed on 14 November 2023)) (Supplementary Table S1). ST was determined using MLSTFinder databases (https://cge.cbs.dtu.dk/services/MLST/ (accessed on 14 November 2023)) [29] and capsule loci with Pathogenwatch [30].

4.5. Plasmid Analysis

The plasmid content of the isolates provided by short reads was analyzed using PlasmidFinder 2.1 (https://cge.cbs.dtu.dk (accessed on 14 November 2023)) and multilocus sequence typing with pMLST (Table 1). For complete plasmid analysis, a long-read approach was used. Each representative pulsotype was sequenced using single-molecule real-time (SMRT) technology (PacBio, Sequel II system, San Diego, CA, USA) and Flye (https://usegalaxy.org/ (accessed on 14 November 2023)) for de novo assembly. Further plasmid annotation was performed using the Bakta annotation pipeline [31] and further polished with the Basic Local Alignment Search Tool (BLAST) and ISfinder. All sequences were deposited in the ENA database (Study ID: PRJEB52486). Plasmid sequences were compared and visualized using Easyfig2.1 [32].

5. Conclusions

Our data indicate the emergence and dissemination of a new lineage of ST15 K. pneumoniae co-producing blaVIM-1 and blaCTX-M-15 in Andalusian hospitals. The acquisition of a new resistance determinant in an area in which CTX-M-15-producing ST15 is endemic may facilitate spread between centers.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antibiotics12121727/s1, Figure S1: Clonal relatedness of Xbal-digested DNA by pulsed-field gel electrophoresis analysis (PFGE); Figure S2: Matrix of 1133 out of 4891 alleles; not taking into account missing values of K. pneumoniae ST15 producing blaVIM-1 and blaCTX-M-15, the 13 contemporary genomes of ST15 isolates from other centers in the region and the 2 genomes of VIM-1-producing ST15 from Spanish regions other than Andalusia; Table S1: Antimicrobial resistance determinants of K. pneumoniae ST15 producing blaVIM-1 and blaCTX-M-15.

Author Contributions

Methodology, P.P.-P.; Validation, A.G.-d.-T. and L.L.-C.; Formal analysis, P.P.-P., A.G.-d.-T., I.P.-C. and L.L.-C.; Investigation, P.P.-P., A.G.-d.-T., E.R.-V., L.L.-C., F.F.-Á.d.L. and A.P.; Resources, A.P.; Data curation, P.P.-P.; Writing—original draft, P.P.-P. and L.L.-C.; Writing—review and editing, A.G.-d.-T., I.P.-C., E.R.-V., F.F.-Á.d.L. and A.P. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain and Consejería de Salud y Familias, Junta de Andalucía: RH-0136-2020.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within this article and Supplementary Materials. WGS data are available in the ENA database (Bioproject ID: PRJEB52486).

Acknowledgments

The authors thank the Reference Laboratory, Program for the Prevention and Control of Healthcare-Associated Infections and Antimicrobial Stewardship, in Andalucía (PIRASOA, Servicio Andaluz de Salud) for its collaboration.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Hernando-Amado, S.; Coque, T.M.; Baquero, F.; Martínez, J.L. Defining and combating antibiotic resistance from One Health and Global Health perspectives. Nat. Microbiol. 2019, 4, 1432–1442. [Google Scholar] [CrossRef] [PubMed]
  2. World Health Organization. Global Action Plan on Antimicrobial Resistance; World Health Organization: Geneva, Switzerland, 2017; Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed on 10 November 2023).
  3. Bonomo, R.A.; Burd, E.M.; Conly, J.; Limbago, B.M.; Poirel, L.; Segre, J.A.; Westblade, L.F. Carbapenemase-Producing Organisms: A Global Scourge. Clin. Infect. Dis. 2018, 66, 1290–1297. [Google Scholar] [CrossRef] [PubMed]
  4. Martin, R.M.; Bachman, M.A. Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae. Front. Cell. Infect. Microbiol. 2018, 8, 4. [Google Scholar] [CrossRef] [PubMed]
  5. Pitout, J.D.; Nordmann, P.; Poirel, L. Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance. Antimicrob. Agents Chemother. 2015, 59, 5873–5884. [Google Scholar] [CrossRef] [PubMed]
  6. Wyresk, K.L.; Lam, M.M.C.; Holt, K.E. Population genomics of Klebsiella pneumoniae. Nat. Rev. Microbiol. 2020, 18, 344–359. [Google Scholar] [CrossRef] [PubMed]
  7. San Millan, A. Evolution of Plasmid-Mediated Antibiotic Resistance in the Clinical Context. Trends Microbiol. 2018, 26, 978–985. [Google Scholar] [CrossRef] [PubMed]
  8. Oteo, J.; Ortega, A.; Bartolomé, R.; Bou, G.; Conejo, C.; Fernández-Martínez, M.; González-López, J.J.; Martínez-García, L.; Martínez-Martínez, L.; Merino, M.; et al. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob. Agents Chemother. 2015, 59, 3406–3412. [Google Scholar] [CrossRef] [PubMed]
  9. Machuca, J.; López-Cerero, L.; Fernández-Cuenca, F.; Mora-Navas, L.; Mediavilla-Gradolph, C.; López-Rodríguez, I.; Pascual, A. OXA-48-Like-Producing Klebsiella pneumoniae in Southern Spain in 2014–2015. Antimicrob. Agents Chemother. 2018, 63, e01396-18. [Google Scholar] [CrossRef]
  10. Rodrigues, C.; Machado, E.; Ramos, H.; Peixe, L.; Novais, Â. Expansion of ESBL-producing Klebsiella pneumoniae in hospitalized patients: A successful story of international clones (ST15, ST147, ST336) and epidemic plasmids (IncR, IncFIIK). Int. J. Med. Microbiol. 2014, 304, 1100–1108. [Google Scholar] [CrossRef]
  11. Markovska, R.; Stoeva, T.; Boyanova, L.; Stankova, P.; Pencheva, D.; Keuleyan, E.; Murjeva, M.; Sredkova, M.; Ivanova, D.; Lazarova, G.; et al. Dissemination of successful international clone ST15 and clonal complex 17 among Bulgarian CTX-M-15 producing K. pneumoniae isolates. Diagn. Microbiol. Infect. Dis. 2017, 89, 310–313. [Google Scholar] [CrossRef]
  12. Perez-Palacios, P.; Delgado-Valverde, M.; Gual-de-Torrella, A.; Oteo-Iglesias, J.; Pascual, Á.; Fernandez-Cuenca, F. Co-transfer of plasmid-encoded bla carbapenemases genes and mercury resistance operon in high-risk clones of Klebsiella pneumoniae. Appl. Microbiol. Biotechnol. 2021, 105, 9231–9242. [Google Scholar] [CrossRef] [PubMed]
  13. He, S.; Hickman, A.B.; Varani, A.M.; Siguier, P.; Chandler, M.; Dekker, J.P.; Dyda, F. Insertion Sequence IS26 Reorganizes Plasmids in Clinically Isolated Multidrug-Resistant Bacteria by Replicative Transposition. mBio 2015, 6, e00762. [Google Scholar] [CrossRef] [PubMed]
  14. Harmer, C.J.; Hall, R.M. IS26-mediated formation of transposons carrying antibiotic resistance genes. mSphere 2016, 1, e00038-16. [Google Scholar] [CrossRef]
  15. Ford, P.J.; Avison, M.B. Evolutionary mapping of the SHV β-lactamase and evidence for two separate IS26-dependent blaSHV mobilization events from the Klebsiella pneumoniae chromosome. J. Antimicrob. Chemother. 2004, 54, 69–75. [Google Scholar] [CrossRef] [PubMed]
  16. Zhao, Q.Y.; Zhu, J.H.; Cai, R.M.; Zheng, X.R.; Zhang, L.J.; Chang, M.X.; Lu, Y.W.; Fang, L.X.; Sun, J.; Jiang, H.X. IS26 Is Responsible for the Evolution and Transmission of blaNDM-Harboring Plasmids in Escherichia coli of Poultry Origin in China. mSystems 2021, 6, e0064621. [Google Scholar] [CrossRef] [PubMed]
  17. Partridge, S.R.; Kwong, S.M.; Firth, N.; Jensen, S.O. Mobile Genetic Elements Associated with Antimicrobial Resistance. Clin. Microbiol. Rev. 2018, 31, e00088-17. [Google Scholar] [CrossRef] [PubMed]
  18. Sánchez-Romero, I.; Asensio, A.; Oteo, J.; Muñoz-Algarra, M.; Isidoro, B.; Vindel, A.; Alvarez-Avello, J.; Balandín-Moreno, B.; Cuevas, O.; Fernández-Romero, S.; et al. Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: Molecular basis, clinical risk factors, and outcome. Antimicrob. Agents Chemother. 2012, 56, 420–427. [Google Scholar] [CrossRef]
  19. Campos, A.C.; Albiero, J.; Ecker, A.B.; Kuroda, C.M.; Meirelles, L.E.; Polato, A.; Tognim, M.C.; Wingeter, M.A.; Teixeira, J.J. Outbreak of Klebsiella pneumoniae carbapenemase–producing K pneumoniae: A systematic review. Am. J. Infect. Control 2016, 44, 1374–1380. [Google Scholar] [CrossRef]
  20. Marí-Almirall, M.; Ferrando, N.; Fernández, M.J.; Cosgaya, C.; Viñes, J.; Rubio, E.; Cuscó, A.; Muñoz, L.; Pellice, M.; Vergara, A.; et al. clonal spread and intra- and inter-species plasmid dissemination associated with Klebsiella pneumoniae carbapenemase-producing Enterobacterales during a hospital outbreak in Barcelona, Spain. Front. Microbiol. 2021, 12, 781127. [Google Scholar] [CrossRef]
  21. Zhou, K.; Lokate, M.; Deurenberg, R.H.; Tepper, M.; Arends, J.P.; Raangs, E.G.; Lo-Ten-Foe, J.; Grundmann, H.; Rossen, J.W.; Friedrich, A.W. Use of whole-genome sequencing to trace, control and characterize the regional expansion of extended-spectrum β-lactamase producing ST15 Klebsiella pneumoniae. Sci. Rep. 2016, 6, 20840. [Google Scholar] [CrossRef]
  22. David, S.; Reuter, S.; Harris, S.R.; Glasner, C.; Feltwell, T.; Argimon, S.; Abudahab, K.; Goater, R.; Giani, T.; Errico, G.; et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat. Microbiol. 2019, 4, 1919–1929. [Google Scholar] [CrossRef] [PubMed]
  23. French, C.E.; Coope, C.; Conway, L.; Higgins, J.P.T.; McCulloch, J.; Okoli, G.; Patel, B.C.; Oliver, I. Control of carbapenemase-producing Enterobacteriaceae outbreaks in acute settings: An evidence review. J. Hosp. Infect. 2017, 95, 3–45. [Google Scholar] [CrossRef] [PubMed]
  24. Abramowicz, L.; Gerard, M.; Martiny, D.; Delforge, M.; De Wit, S.; Konopnicki, D. Infections due to carbapenemase-producing bacteria, clinical burden, and impact of screening strategies on outcome. Med. Mal. Infect. 2020, 50, 658–664. [Google Scholar] [CrossRef] [PubMed]
  25. Tenover, F.C.; Arbeit, R.D.; Goering, R.V.; Mickelsen, P.A.; Murray, B.E.; Persing, D.H.; Swaminathan, B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J. Clin. Microbiol. 1995, 33, 2233–2239. [Google Scholar] [CrossRef] [PubMed]
  26. David, S.; Cohen, V.; Reuter, S.; Sheppard, A.E.; Giani, T.; Parkhill, J.; Rossolini, G.M.; Feil, E.J.; Grundmann, H.; Aanensen, D.M. Integrated chromosomal and plasmid sequence analyses reveal diverse modes of carbapenemase gene spread among Klebsiella pneumoniae. Proc. Natl. Acad. Sci. USA 2020, 117, 25043–25054. [Google Scholar] [CrossRef] [PubMed]
  27. Zhou, H.; Liu, W.; Qin, T.; Liu, C.; Ren, H. Defining and Evaluating a Core Genome Multilocus Sequence Typing Scheme for Whole-Genome Sequence-Based Typing of Klebsiella pneumoniae. Front. Microbiol. 2017, 8, 371. [Google Scholar] [CrossRef] [PubMed]
  28. Spencer, M.D.; Winglee, K.; Passaretti, C.; Earl, A.M.; Manson, A.L.; Mulder, H.P.; Sautter, R.L.; Fodor, A.A. Whole Genome Sequencing detects Inter-Facility Transmission of Carbapenem-resistant Klebsiella pneumoniae. J. Infect. 2019, 78, 187–199. [Google Scholar] [CrossRef] [PubMed]
  29. Larsen, M.V.; Cosentino, S.; Rasmussen, S.; Friis, C.; Hasman, H.; Marvig, R.L.; Jelsbak, L.; Sicheritz-Pontén, T.; Ussery, D.W.; Aarestrup, F.M.; et al. Multilocus sequence typing of total genome sequenced bacteria. J. Clin. Micobiol. 2012, 50, 1355–1361. [Google Scholar] [CrossRef]
  30. Wick, R.R.; Heinz, E.; Holt, K.E.; Wyres, K.L. Kaptive Web: User-Friendly Capsule and Lipopolysaccharide Serotype Prediction for Klebsiella Genomes. J. Clin. Microbiol. 2018, 56, e00197-18. [Google Scholar] [CrossRef]
  31. Schwengers, O.; Jelonek, L.; Dieckmann, M.A.; Beyvers, S.; Blom, J.; Goesmann, A. Bakta: Rapid and standardized annotation of bacterial genomes via alignment-free sequence identification. Microb. Genom. 2021, 7, 000685. [Google Scholar] [CrossRef]
  32. Sullivan, M.J.; Petty, N.K.; Beatson, S.A. Easyfig: A genome comparison visualizer. Bioinformatics 2011, 27, 1009–1010. [Google Scholar] [CrossRef]
Antibiotics 12 01727 g001
Figure 1. Graphical representation of possible pathways of interhospital spread for this study.
Figure 1. Graphical representation of possible pathways of interhospital spread for this study.
Antibiotics 12 01727 g001
Antibiotics 12 01727 g002
Figure 2. IncR plasmids harboring blaVIM-1 and blaCTX-M-15 from 7 K. pneumoniae ST15 isolates. blaVIM-1 is shown in red, blaCTX-M-15, blaOXA-1 and blaTEM-1 are shown in dark green, IS are shown in blue and metal resistance operons are shown in yellow.
Figure 2. IncR plasmids harboring blaVIM-1 and blaCTX-M-15 from 7 K. pneumoniae ST15 isolates. blaVIM-1 is shown in red, blaCTX-M-15, blaOXA-1 and blaTEM-1 are shown in dark green, IS are shown in blue and metal resistance operons are shown in yellow.
Antibiotics 12 01727 g002
Table 1. Relevant characteristics of the isolates of K. pneumoniae ST15 producing blaVIM-1 and blaCTX-M-15.
Table 1. Relevant characteristics of the isolates of K. pneumoniae ST15 producing blaVIM-1 and blaCTX-M-15.
Isolate (n°)Isolation DatePulse TypeblaSourceHospitalcgMLSTCapsule TypePlasmids
ESBL 1CPase 2
201778714 August 2017P1CTX-M-15VIM-1BloodstreamInfanta Elena3266KL64/O2v1IncR, ColpVC
201791715 September 2017P1CTX-M-15VIM-1UrineInfanta ElenaN.A 3 N.A
2018025616 March 2018P2CTX-M-15VIM-1Rectal swabVirgen Macarena3266KL64/O2v1IncR, ColpVC
2018051624 May 2018P2CTX-M-15VIM-1BloodstreamInfanta ElenaN.A N.A
201807845 September 2018P3CTX-M-15VIM-1Skin and soft tissuesInfanta ElenaN.A N.A
2018079715 September 2018P3CTX-M-15VIM-1Skin and soft tissuesInfanta ElenaN.A N.A
201809125 October 2018P3CTX-M-15VIM-1Rectal swabInfanta Elena3266KL64/O2v1IncR, ColpVC
2018108629 November 2018P1CTX-M-15VIM-1UrineInfanta ElenaN.A N.A
2018108730 November 2018P1CTX-M-15VIM-1Rectal swabInfanta ElenaN.A N.A
2018113013 December 2018P4CTX-M-15VIM-1BloodstreamVirgen Macarena3266KL64/O2v1IncR, ColpVC
2019009031 January 2019P5CTX-M-15VIM-1RespiratoryJuan Ramón Jimenez3266KL64/O2v1IncR, ColpVC
201900957 February 2019P6CTX-M-15VIM-1UrineJuan Ramón Jimenez3266KL64/O2v1IncR, ColpVC
2019009613 February 2019P7CTX-M-15VIM-1UrineVirgen MacarenaN.A 3 N.A
2019017513 March 2019P4CTX-M-15VIM-1UrineVirgen MacarenaN.A N.A
2019019122 February 2019P7CTX-M-15VIM-1RespiratoryJuan Ramón Jimenez3266KL64/O2v1IncR, ColpVC
201902602 May 2019P4CTX-M-15VIM-1Rectal swabVirgen MacarenaN.A N.A
201902687 May 2019P5CTX-M-15VIM-1Rectal swabVirgen MacarenaN.A N.A
2019028612 May 2019P7CTX-M-15VIM-1BloodstreamVirgen MacarenaN.A N.A
2019030317 May 2019P4CTX-M-15VIM-1Rectal swabVirgen MacarenaN.A N.A
201904021 July 2019P7CTX-M-15VIM-1Rectal swabVirgen MacarenaN.A N.A
201904031 July 2019P7CTX-M-15VIM-1Rectal swabVirgen MacarenaN.A N.A
2019050424 July 2019P4CTX-M-15VIM-1Skin and soft tissuesVirgen MacarenaN.A N.A
2019052314 August 2019P4CTX-M-15VIM-1Rectal swabVirgen MacarenaN.A N.A
2019052414 August 2019P4CTX-M-15VIM-1Rectal swabVirgen MacarenaN.A N.A
2019052614 August 2019P7CTX-M-15VIM-1Skin and soft tissuesVirgen MacarenaN.A 3 N.A
201906435 September 2019P2CTX-M-15VIM-1RespiratoryInfanta Elena5114KL64/O2v1IncR, ColpVC
2019069324 September 2019P5CTX-M-15VIM-1Skin and soft tissuesDe la MercedN.A N.A
2019071714 October 2019P7CTX-M-15VIM-1UrineVirgen MacarenaN.A N.A
2019094420 December 2019P5CTX-M-15VIM-1UrineVirgen MacarenaN.A N.A
1 ESBL: extended-spectrum β-lactamase. 2 CPase: carbapenemases. 3 N.A: not analyzed.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pérez-Palacios, P.; Gual-de-Torrella, A.; Portillo-Calderón, I.; Recacha-Villamor, E.; Franco-Álvarez de Luna, F.; Lopez-Cerero, L.; Pascual, A. Interhospital Spread of blaVIM-1- and blaCTX-M-15-Producing K. pneumoniae ST15 on an IncR Plasmid in Southern Spain. Antibiotics 2023, 12, 1727. https://doi.org/10.3390/antibiotics12121727

AMA Style

Pérez-Palacios P, Gual-de-Torrella A, Portillo-Calderón I, Recacha-Villamor E, Franco-Álvarez de Luna F, Lopez-Cerero L, Pascual A. Interhospital Spread of blaVIM-1- and blaCTX-M-15-Producing K. pneumoniae ST15 on an IncR Plasmid in Southern Spain. Antibiotics. 2023; 12(12):1727. https://doi.org/10.3390/antibiotics12121727

Chicago/Turabian Style

Pérez-Palacios, Patricia, Ana Gual-de-Torrella, Ines Portillo-Calderón, Esther Recacha-Villamor, Francisco Franco-Álvarez de Luna, Lorena Lopez-Cerero, and Alvaro Pascual. 2023. "Interhospital Spread of blaVIM-1- and blaCTX-M-15-Producing K. pneumoniae ST15 on an IncR Plasmid in Southern Spain" Antibiotics 12, no. 12: 1727. https://doi.org/10.3390/antibiotics12121727

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop